Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.46 |
| ▸ | XIAP | P98170 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655914 | 0.85 | XIAP (0.53) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31655974 | 0.85 | RIPK1 (0.58) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31655954 | 0.83 | RIPK1 (0.43) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31655919 | 0.81 | RIPK1 (0.48) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31656008 | 0.80 | RIPK1 (0.47) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31655925 | 0.78 | RIPK1 (0.45) | RIPK1XIAP | |
| SCHEMBL31655956 | 0.77 | RIPK1 (0.44) | RIPK1NPC1RAB9ASCN9A | |
| SCHEMBL31655917 | 0.76 | RIPK1 (0.46) | RIPK1XIAPNPC1RAB9ASCN9A | |
| SCHEMBL31655953 | 0.75 | RIPK1 (0.62) | RIPK1XIAPNPC1RAB9A | |
| SCHEMBL31655855 | 0.75 | RIPK1 (0.60) | RIPK1XIAPSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582414-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-07-09 | — | — | EP | claimed |
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-4582414-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885XIAP 56/4885NPC1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.